---
title: "Tonix Pharmaceuticals posts investor deck focused on TONMYA fibromyalgia launch and pipeline updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294058072.md"
description: "Tonix Pharmaceuticals released an investor deck highlighting commercial traction for TONMYA, its first FDA-approved adult fibromyalgia treatment in over 15 years. The company reported $3.7 million in Q1'26 net sales and holds $185.5 million in cash with no debt, extending its runway into early Q2'27. Pipeline updates include a planned Phase 2 study for TNX-4800 (Lyme disease) in H1'27, alongside upcoming studies for TNX-1500 and TNX-2900."
datetime: "2026-07-28T11:30:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294058072.md)
  - [en](https://longbridge.com/en/news/294058072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294058072.md)
generator: "portal-rs"
---

# Tonix Pharmaceuticals posts investor deck focused on TONMYA fibromyalgia launch and pipeline updates

-   Tonix highlighted commercial traction for fibromyalgia drug TONMYA, launched Nov. 17, 2025; first FDA-approved adult fibromyalgia treatment in 15+ years. \* Reported 1Q’26 net sales of $3.7 million; $5.1 million from Nov. 17, 2025 to Mar. 31, 2026. \* Disclosed ~$185.5 million cash and cash equivalents as of March 31, 2026; no debt; runway expected into early Q2’27. \* Pipeline update included TNX-4800 Lyme disease prevention adaptive Phase 2 field study planned for 1H’27 in the U.S. \* Other planned studies: TNX-1500 organ transplant rejection Phase 2 in 2H’26; TNX-2900 Prader-Willi syndrome Phase 2 in 1Q’27. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)

## Related News & Research

- [Tonix CEO Seth Lederman acquires 2,000 common shares for $27,580](https://longbridge.com/en/news/297513102.md)
- [Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock](https://longbridge.com/en/news/297522420.md)
- [Avient’s Dyneema to debut SK80 mooring fiber at SMM trade fair](https://longbridge.com/en/news/297191045.md)
- [Does Starbucks’ Fiber Snack Partnership With Floura Fiber Reframe Its Turnaround Menu Strategy (SBUX)?](https://longbridge.com/en/news/297558106.md)
- [Tonix publishes investor deck highlighting TONMYA fibromyalgia launch and pipeline updates](https://longbridge.com/en/news/294741794.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**